US 11,793,847 B2
Methods of treating endometrial cancer using hemp extract
Alexandra M. Capano, Philadelphia, PA (US); Pradeep Singh Tanwar, Fletcher (AU); and Alex Nance, Georgetown, KY (US)
Assigned to Ecofibre USA Inc., Georgetown, KY (US); and The University of Newcastle, Callaghan (AU)
Filed by Ecofibre USA Inc., Georgetown, KY (US); and The University of Newcastle, Callaghan (AU)
Filed on Oct. 26, 2022, as Appl. No. 18/50,021.
Claims priority of provisional application 63/263,018, filed on Oct. 26, 2021.
Claims priority of provisional application 63/263,026, filed on Oct. 26, 2021.
Claims priority of provisional application 63/263,020, filed on Oct. 26, 2021.
Prior Publication US 2023/0131068 A1, Apr. 27, 2023
Int. Cl. A61K 31/05 (2006.01); A61K 36/185 (2006.01); A61P 35/00 (2006.01); A61K 31/015 (2006.01); A61K 31/045 (2006.01); A61K 31/216 (2006.01); A61K 31/352 (2006.01); A61K 31/355 (2006.01); A61K 31/7048 (2006.01); A61K 31/395 (2006.01); A61K 33/243 (2019.01); A61K 31/01 (2006.01); A61K 31/198 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/4745 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 39/395 (2006.01)
CPC A61K 36/185 (2013.01) [A61K 31/01 (2013.01); A61K 31/015 (2013.01); A61K 31/045 (2013.01); A61K 31/05 (2013.01); A61K 31/198 (2013.01); A61K 31/216 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/352 (2013.01); A61K 31/355 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/5545 (2017.08); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] 8 Claims
 
1. A method of treatment of endometrial cancer comprising administering to a patient an effective amount of a chemotherapeutic agent selected from the group consisting of: paclitaxel, carboplatin, doxorubicin, cisplatin, docetaxel, gemcitabine, capecitabine, and combinations thereof; and coadministering an effective amount of a composition comprising a cannabis extract (CE), said CE comprising cannabidiol (CBD) at a concentration of between 60% and 99% by weight of the CE and having a pH of between 3.5 and 6, wherein the composition is for intravaginal delivery.